|Bid||331.00 x 200|
|Ask||342.64 x 200|
|Day's Range||329.42 - 333.53|
|52 Week Range||246.71 - 342.50|
|PE Ratio (TTM)||11.54|
|Expense Ratio (net)||0.47%|
After Cancer-Cure Makers Make Great Takeover Stocks was published in the October 24th issue of Forbes, a number of readers asked if there was a safe way to invest in biotech. Forbes reader Alice Lane asked the questions that seem to be on many people's minds. Here are my answers.
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline. To do this, I use CELG options instead of trading its underlying equity. Click to Enlarge Fundamentally, Celgene is not cheap.
iShares Trust – iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) is trading with a trailing P/E of 11.6x, which is lower than the industry average of 18.6x. Although some investors may jumpRead More...
Shares of biotechnology giant Amgen, Inc. (NASDAQ:AMGN) are higher by just about 27% for the year-to-date but in the bigger picture really just started on a major new breakout rally. Healthcare stocks as a sector and biotechnology stocks as a group and as represented by the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) have done well overall so far in 2017 and promise more upside.
Wall Street has been confused about the prospects of the pharmaceutical industry for almost two years. The 2016 U.S. presidential campaign and election results wreaked havoc with their stocks. Allergan plc Ordinary Shares (NYSE:AGN) stock, in general, follows a trend on the industry from the stock price perspective.
The treasury secretary gave an ’absolute guarantee' that a tax overhaul would be signed into law by the end of the year. Yahoo Finance’s Alexis Christoforous, Dan Roberts, and Kevin Mahn, CIO of Hennion & Walsh Asset Management discuss whether or not investors should trust Mnuchin’s tax prediction.
Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.
Alan Valdes, Director of Floor Operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss Q3 earnings and if investors have gotten too optimistic.
CNBC's Meg Tirrell reports on California's proposed bill requiring companies to give 60 days notice in advance when they plan to raise drug prices over a certain threshold.